Valproic acid: A new narrative on its features and effects in traumatic brain injury

Glenn Wakam; Michael Kemp; Hasan Alam

doi:10.1016/B978-0-12-823347-4.00007-5

Valproic acid: A new narrative on its features and effects in traumatic brain injury

Glenn Wakam, Michael Kemp, Hasan Alam

Surgery, Trauma and Critical Care Division

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Traumatic brain injury is a major cause of morbidity and mortality worldwide. Currently, the only treatment is supportive, with an emphasis on prevention of secondary injury. Our lab has over a decade of experience investigating histone deacetylase inhibitors (HDACIs), mainly valproic acid (VPA), as a treatment to improve survival and recovery after traumatic brain injury. In this chapter, we will review the cellular changes that occur after traumatic brain injury, the promising results of preclinical use of VPA in TBI, and the future of VPA use in traumatic brain injury.

Original language	English (US)
Title of host publication	Diagnosis and Treatment of Traumatic Brain Injury
Subtitle of host publication	The Neuroscience of Traumatic Brain Injury
Publisher	Elsevier Inc
Pages	477-484
Number of pages	8
ISBN (Electronic)	9780128233474
ISBN (Print)	9780128233481
DOIs	https://doi.org/10.1016/B978-0-12-823347-4.00007-5
State	Published - Jan 1 2022

Keywords

Acetylation
Epigenetics
Histone deacetylase inhibitor
Neurodegeneration
Neurologic outcomes
Neuroplasticity
Pro-survival
Traumatic brain injury
Valproic acid

ASJC Scopus subject areas

Medicine(all)
Neuroscience(all)

Access to Document

10.1016/B978-0-12-823347-4.00007-5

Cite this

@inbook{1cf20dfef58f4ba991accc93b068fa79,

title = "Valproic acid: A new narrative on its features and effects in traumatic brain injury",

abstract = "Traumatic brain injury is a major cause of morbidity and mortality worldwide. Currently, the only treatment is supportive, with an emphasis on prevention of secondary injury. Our lab has over a decade of experience investigating histone deacetylase inhibitors (HDACIs), mainly valproic acid (VPA), as a treatment to improve survival and recovery after traumatic brain injury. In this chapter, we will review the cellular changes that occur after traumatic brain injury, the promising results of preclinical use of VPA in TBI, and the future of VPA use in traumatic brain injury.",

keywords = "Acetylation, Epigenetics, Histone deacetylase inhibitor, Neurodegeneration, Neurologic outcomes, Neuroplasticity, Pro-survival, Traumatic brain injury, Valproic acid",

author = "Glenn Wakam and Michael Kemp and Hasan Alam",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-823347-4.00007-5",

language = "English (US)",

isbn = "9780128233481",

pages = "477--484",

booktitle = "Diagnosis and Treatment of Traumatic Brain Injury",

publisher = "Elsevier Inc",

}

TY - CHAP

T1 - Valproic acid

T2 - A new narrative on its features and effects in traumatic brain injury

AU - Wakam, Glenn

AU - Kemp, Michael

AU - Alam, Hasan

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Traumatic brain injury is a major cause of morbidity and mortality worldwide. Currently, the only treatment is supportive, with an emphasis on prevention of secondary injury. Our lab has over a decade of experience investigating histone deacetylase inhibitors (HDACIs), mainly valproic acid (VPA), as a treatment to improve survival and recovery after traumatic brain injury. In this chapter, we will review the cellular changes that occur after traumatic brain injury, the promising results of preclinical use of VPA in TBI, and the future of VPA use in traumatic brain injury.

AB - Traumatic brain injury is a major cause of morbidity and mortality worldwide. Currently, the only treatment is supportive, with an emphasis on prevention of secondary injury. Our lab has over a decade of experience investigating histone deacetylase inhibitors (HDACIs), mainly valproic acid (VPA), as a treatment to improve survival and recovery after traumatic brain injury. In this chapter, we will review the cellular changes that occur after traumatic brain injury, the promising results of preclinical use of VPA in TBI, and the future of VPA use in traumatic brain injury.

KW - Acetylation

KW - Epigenetics

KW - Histone deacetylase inhibitor

KW - Neurodegeneration

KW - Neurologic outcomes

KW - Neuroplasticity

KW - Pro-survival

KW - Traumatic brain injury

KW - Valproic acid

UR - http://www.scopus.com/inward/record.url?scp=85137576836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137576836&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-823347-4.00007-5

DO - 10.1016/B978-0-12-823347-4.00007-5

M3 - Chapter

AN - SCOPUS:85137576836

SN - 9780128233481

SP - 477

EP - 484

BT - Diagnosis and Treatment of Traumatic Brain Injury

PB - Elsevier Inc

ER -

Valproic acid: A new narrative on its features and effects in traumatic brain injury

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this